R&D channel feed – Endpoints News

R&D channel feed

#ASCO21: Ahead of August PDUFA date, Astellas and Seagen sweeten Padcev pitch with new data

5 years ago

#ASCO21: J&J busts out a small update for its antibody-TKI combo in lung cancer — whetting appetites as FDA thinks it over

5 years ago

Acceleron uncorks more mid-stage data for PAH drug sotatercept as part of the drug's resurrection campaign

5 years ago

Sarepta touts clean data for commercial grade Duchenne gene therapy, clearing key hurdle to PhIII

5 years ago

Novo Nordisk continues pushing beyond diabetes, netting PhII win for former Corvidia kidney program

5 years ago

Incyte keeps rolling on topical cream for JAK inhibitor, passing two PhIII tests in vitiligo

5 years ago

Days ahead of Amgen split, Cytokinetics reads out post-hoc data suggesting heart drug works better in sicker patients — but can the CEO win over skeptics?

5 years ago

#ACC21: Novartis' Entresto takes its 2nd failure of the weekend at ACC, showing no benefit in most dire heart failure patients

5 years ago

Sanofi, GlaxoSmithKline jump back into the PhIII race for a Covid vaccine — as the winners congregate behind the finish line

5 years ago

#ACC21: AstraZeneca's Farxiga missed big on Covid-19 study, but it's taking SGLT2 safety data as a silver lining

5 years ago

#ACC21: Regeneron's Evkeeza shows promise in curbing high triglycerides, but will genetic disparities limit use?

5 years ago

#ACC21: Pfizer, Bristol Myers' Eliquis flops in post-heart surgery patients, spurring an 'unexplained signal' in certain deaths

5 years ago

#ACC21: Bristol Myers backs up its case for heart drug mavacamten as FDA weighs app in cardiomyopathy

5 years ago

BARDA slows its $9B engine for new Covid-19 therapeutics

5 years ago

Gene therapy player turned kidney specialist Vera drops a dud in leadup to Nasdaq, pricing well below range

5 years ago

Gene therapy from Biogen's $800M buyout flops in mid-stage study, dealing blow to new ambitions

5 years ago

Kept an ocean away from its scientific advisors, Shanghai's Elpiscience keeps up the clinical progress, refuels for its I/O pipeline

5 years ago

Pfizer publishes clinical trial diversity data from past decade, showing there's much work to be done

5 years ago

Weeks after Keytruda CRL in high-risk TNBC, Merck claims a win after data mature. How soon will it return to FDA?

5 years ago

Amgen, AstraZeneca bolster their case for breakthrough asthma program as FDA considers taking up a review

5 years ago

Biogen pushes in a fresh stack of chips and starts prepping a global R&D game plan after watching the cards turn on early thrombolytic data

5 years ago

Bayer claims another win on its CKD and diabetes hopeful, though the question remains over just how big it is

5 years ago

Ionis scraps CF program in another setback for the disease and the company

5 years ago

AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it's adding more heat under Gilead's Trodelvy

5 years ago

First page Previous page 170 171 172173174 175 176 Next page Last page